
Viatris Inc.
VTRSHealthcare|Drug Manufacturers - Specialty & Generic|US
$19.91
+0.94 (+4.96%)
DCF Value
$19.78
Cash / Share
$1.65
Next Earnings Report
Feb 25, 2027
EPS est. $0.60 · Revenue est. $3.72B
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Jun 15, 2026 (424B5). Possible dilution.
Upcoming Data Readouts (12)
Nov 2026
Est. completion
Dec 2026
Est. completion
P4Dry Eye
Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment
NCT07606625n=65
Dec 2026
Est. completion
P3Lupus Erythematosus, Systemic
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576n=451
Jan 2027
Est. completion
P4Erectile Dysfunction Following Radical Prostatectomy
PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)
NCT06875258n=198
Mar 2027
Est. completion
Cancer
Naldemedine in Clinical Practice in Cancer Patients With Opioid Induced CONstipation: Clinical Outcomes and Patient Experience
NCT07231796n=100
Mar 2027
Est. completion
P3Lupus Erythematosus, Systemic
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500n=470
May 2027
Est. completion
P3Female Contraception
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
NCT06672016n=1,630
Jun 2027
Est. completion
P4COPD (Chronic Obstructive Pulmonary Disease)
Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD
NCT07816835n=120
Oct 2027
Est. completion
P2SLE - Systemic Lupus Erythematosus
A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)
NCT07266090n=15
Nov 2027
Est. completion
P1P2Neurotrophic Keratopathy
A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy of MR-146: An Open-Label Part 1 in Participants With Stage 1 or 2 Neurotrophic Keratopathy and a Double-Masked Part 2 in Participants With Stage 2 Neurotrophic Keratopathy
NCT07923045n=18
Aug 2029
Est. completion
P3Nephritis, Lupus
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
NCT07201129n=300
Aug 2030
Est. completion
P3MDR-TB
Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)
NCT07486024n=55
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.
NCT06052995Recent Press Releases
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
Nov 5, 2026 · Business Wire
Viatris Reports Third-Quarter 2026 Financial Results
Nov 5, 2026 · PRNewsWire
Viatris Announces Quarterly Dividend
Nov 4, 2026 · PRNewsWire
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
Oct 30, 2026 · PRNewsWire
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
Oct 16, 2026 · PRNewsWire
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
Oct 12, 2026 · Business Wire
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)
Oct 8, 2026 · Newsfile Corp
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Oct 8, 2026 · PRNewsWire
Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
Oct 5, 2026 · PRNewsWire
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
Sep 29, 2026 · PRNewsWire
SEC Filings (60)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 6, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Nov 5, 2026 | 8-K | Material event | DocumentIndex |
| Oct 30, 2026 | SC TO-T | Tender offer | DocumentIndex |
| Oct 8, 2026 | SC TO-C | Tender offer | DocumentIndex |
| Oct 8, 2026 | SC TO-C | Tender offer | DocumentIndex |
| Oct 8, 2026 | 8-K | Material event | DocumentIndex |
| Sep 8, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 12, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 6, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 6, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Aug 6, 2026 | 8-K | Material event | DocumentIndex |
| Jul 1, 2026 | 8-K | Material event | DocumentIndex |
| Jun 18, 2026 | 8-K | Material event | DocumentIndex |
| Jun 15, 2026 | 8-K | Material event | DocumentIndex |
| Jun 15, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| Jun 12, 2026 | FWP | DocumentIndex | |
| Jun 12, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| May 15, 2026 | 8-K | Material event | DocumentIndex |
| May 7, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 7, 2026 | 8-K | Material event | DocumentIndex |
| May 5, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 4, 2026 | 8-K | Material event | DocumentIndex |
| Apr 30, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 2, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 2, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 2, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 27, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 26, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 26, 2026 | 8-K | Material event | DocumentIndex |
| Feb 4, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 3, 2026 | 8-K | Material event | DocumentIndex |
| Dec 8, 2025 | 8-K | Material event | DocumentIndex |
| Dec 5, 2025 | 8-K | Material event | DocumentIndex |
| Dec 5, 2025 | 8-K/A | Material event | DocumentIndex |
| Nov 10, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 6, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Nov 6, 2025 | 8-K | Material event | DocumentIndex |
| Oct 24, 2025 | 8-K | Material event | DocumentIndex |
| Oct 24, 2025 | ARS | Annual report to holders | DocumentIndex |